biocon semaglutide signs out-licensing agreement with Ajanta Pharma to market in 26 countries Biocon signs out-licensing agreement with
Description
Retatrutide is a next-generation synthetic peptide acting as a triple receptor agonist, simultaneously targeting GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors
Using a GLP-1
A weight-loss pill that works
A class-action lawsuit filed against CVS Caremark argues that the PBM dropping coverage of Zepbound for Wegovy is illegal
Brian Wojeck, MD, MPH, outlines the clinical considerations sleep medicine specialists will increasingly need to know to treat patients with obesity-related sleep apnea.
